Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences 3D-Culture, Organoids and Organs-on-Chips 2021

Thomas Hartung's Biography

Thomas Hartung, Professor and Doerenkamp-Zbinden Chair for Evidence-based Toxicology, Director of the Center for Alternatives to Animal Testing (CAAT), Johns Hopkins Bloomberg School of Public Health

Thomas Hartung, MD PhD, is the Doerenkamp-Zbinden-Chair for Evidence-based Toxicology in the Department of Environmental Health and Engineering at Johns Hopkins Bloomberg School of Public Health, Baltimore, with a joint appointment at the Whiting School of Engineering. He also holds a joint appointment for Molecular Microbiology and Immunology at the Bloomberg School. He is adjunct affiliate professor at Georgetown University, Washington D.C.. In addition, he holds a joint appointment as Professor for Pharmacology and Toxicology at University of Konstanz, Germany; he also is Director of Centers for Alternatives to Animal Testing (CAAT, of both universities. CAAT hosts the secretariat of the Evidence-based Toxicology Collaboration (, the Good Read-Across Practice Collaboration, the Good Cell Culture Practice Collaboration, the Green Toxicology Collaboration and the Industry Refinement Working Group. As PI, he headed the Human Toxome project funded as an NIH Transformative Research Grant. He is Chief Editor of Frontiers in Artificial Intelligence. He is Consulting Vice-President of AxoSim Inc., New Orleans. He is the former Head of the European Commission’s Center for the Validation of Alternative Methods (ECVAM), Ispra, Italy, and has authored more than 585 scientific publications.

Thomas Hartung Image

From Microphysiological to Micropathophysiolocal Models

Tuesday, 23 March 2021 at 09:45

Add to Calendar ▼2021-03-23 09:45:002021-03-23 10:45:00Europe/LondonFrom Microphysiological to Micropathophysiolocal Models3D-Culture, Organoids and Organs-on-Chips 2021 in

The increasing pace of technological developments of modern cell culture and their integration leads to what is called “disruptive technologies”. The development of alternatives to traditional approaches for product development and safety assessment benefits from this. The combination of cell culture with bioengineering has led to a number of technologies to make cell culture more organo-typic, such as 3D culture, human stem cell-derived systems, perfusion, co-cultures, combinations with scaffolds and sensors etc.. Increasingly, they lead to “organ-on-chip” or even multi-organ “human-on-chip” solutions. By recreating organ architecture, homeostasis of the cell environment and organ functionality, these models mirror more closely the physiological situation. The example of our human iPSC-derived brain organoids is used to illustrate this. The commercial availability of organoids also improves standardization and reproducibility. Efforts for their quality control by Good Cell Culture Practice 2.0 and emerging reporting standards further pave the way to their broad use in academia and drug discovery.

Add to Calendar ▼2021-03-22 00:00:002021-03-23 00:00:00Europe/London3D-Culture, Organoids and Organs-on-Chips 20213D-Culture, Organoids and Organs-on-Chips 2021 in